Seven patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2 more records may belong here and await a decision; they are not counted.
The next term ends in Feb 2032. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Feb 2032
Next term end
6
Patent families
When these terms end
Each bar runs from grant to computed term end. 2016 to 2039.20212026203120362039
2 pending applications: term is not computable until grant.Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2032 · High confidence
Also notable
Ends Jun 2033 · High confidence
Also notable
Ends Mar 2039 · High confidence
Methods of Detecting Gene Fusions
US 10,294,515
Granted 2019. Computed term ends 2032.
Molecular Malignancy in Melanocytic Lesions
US 9,758,829
Granted 2017 and renewed at every maintenance window due so far. Protection runs to 2033.
Methods for Subtyping Diffuse Large B-Cell Lymphoma (DLBCL)
US 11,384,399
The newest of the three, granted 2022. It anchors the portfolio to 2039, later than anything else here.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 21, 2026The maintenance fee for Methods of Detecting Gene Fusions (US 10,294,515) comes due Nov 21, 2026. Unpaid by May 21, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 6 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Methods of Detecting Gene Fusions | 2 in force | to May 2032 |
| Method of Direct Target Sequencing Using Nuclease Protection | 1 in force | to Apr 2039 |
| Methods for Subtyping Diffuse Large B-Cell Lymphoma (DLBCL) | 1 in force | to Mar 2039 |
| Nuclease Protection Methods for Detection of Nucleotide Variants | 1 in force | to Oct 2033 |
| Molecular Malignancy in Melanocytic Lesions | 1 in force | to Jun 2033 |
Patents held now
Soonest term end first.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,268,133 | Methods of Detecting Gene Fusions In force · High confidence | In force | High confidence | |
| US 10,294,515 | Methods of Detecting Gene Fusions In force · High confidence | In force | High confidence | |
| US 9,512,469 | Methods of Co-Detecting Mrna and Small Non-Coding RNA In force · High confidence | In force | High confidence | |
| US 9,758,829 | Molecular Malignancy in Melanocytic Lesions In force · High confidence | In force | High confidence | |
| US 9,765,385 | Nuclease Protection Methods for Detection of Nucleotide Variants In force · High confidence | In force | High confidence | |
| US 11,384,399 | Methods for Subtyping Diffuse Large B-Cell Lymphoma (DLBCL) In force · High confidence | In force | High confidence | |
| US 12,104,206 | Method of Direct Target Sequencing Using Nuclease Protection In force · High confidence | In force | High confidence |
Also on record, not counted in the 7: 2 patents ended · 2 applications pending · 6 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.